全体大会
General Session I
01
MAESTRO-NASH的主要结果：一项针对966名NASH伴肝纤维化患者的关键III期52周系列肝活检研究
GS-001: Primary results from MAESTRO-NASH a pivotal phase 3 52-week serial liver biopsy study in 966 patients with NASH and fibrosis
讲者：Stephen Harrison (San Antonio, TX, United States)
专题：General session I
时间：6月22日10:30-10:45 CET
02
髓细胞IL-8富集与晚期肝细胞癌免疫治疗耐药有关
GS-002-YI: Myeloid IL-8 enrichment associates with immunotherapy resistance in advanced hepatocellular carcinoma
讲者：Tsz Tung Kwong (Shatin Tin, Hong Kong SAR)
专题：General session I
时间：6月22日10:45-11:00 CET
03
利伐沙班可改善中度肝功能障碍肝硬化患者的生存率和失代偿——来自一项双盲安慰剂对照试验
GS-003: Rivaroxaban improves survival and decompensation in cirrhotic patients with moderate liver dysfunction. Double-blind, placebo-controlled trial
讲者：Angela Puente Sanchez (Santander, Spain)
专题：General session I
时间：6月22日11:00-11:15 CET
04
父母罹患酒精相关性肝病时子女的不良健康结局——来自丹麦的一项全国性队列研究
GS-004-YI: Vulnerable offspring: a nationwide Danish cohort study of adverse health outcomes in offspring of parents with alcohol-related liver disease compared to controls
讲者：Gro Askgaard (Aarhus, Denmark)
专题：General session I
时间：6月22日11:45-12:00 CET
05
CD8+T细胞中IL-2通路的选择性激活驱动对乙型肝炎病毒（HBV）的抗病毒活性
GS-005: Selective activation of the IL-2 pathway in CD8+ T cells drives antiviral activity to Hepatitis B Virus (HBV)
讲者：Matteo Iannacone (Milano, Italy)
专题：General session I
时间：6月22日12:00-12:15 CET
06
头孢曲松对比不使用抗生素预防Child-Pugh A肝硬化合并急性静脉曲张出血患者感染的随机对照试验
GS-006: Randomised controlled trial of ceftriaxone versus no antibiotic to prevent infection in patients with Child-Pugh A cirrhosis with acute variceal bleeding
讲者：Anany Gupta (New Delhi, India)
专题：General session I
时间：6月22日12:15-12:30 CET
全体大会
General Session II
07
粪菌移植可恢复晚期肝硬化患者的肠道屏障功能并增强氨代谢——来自一项随机单盲安慰剂对照试验
GS-007: Faecal microbiota transplant restores gut barrier function and augments ammonia metabolism in patients with advanced cirrhosis: a randomised single-blind placebo-controlled trial
讲者：Lindsey A Edwards (London, United Kingdom)
专题：General session II
时间：6月23日10:30-10:45 CET
08
纳曲酮在肝硬化患者戒酒和减少酒精需求方面安全且有效——来自一项双盲随机安慰剂对照试验
GS-008-YI: Naltrexone is safe and effective in achieving abstinence and reducing alcohol craving in cirrhotic patients : a double blind randomized placebo controlled trial
讲者：Manasa Alla (New Delhi, India)
专题：General session II
时间：6月23日10:45-11:00 CET
09
内镜袖状胃成形术是脂肪性肝炎患者的有效治疗方法——来自一项前瞻性多中心随机试验
GS-009: Endoscopy sleeve gastroplasty is an effective treatment in steatohepatitis patients: a prospective, multicenter, randomized trial
讲者：Javier Abad Guerra (Madrid, Spain)
专题：General session II
时间：6月23日11:00-11:15 CET
10
一种综合的多组学方法定义了与人类肝纤维化中细胞状态和染色质组织改变相关的治疗途径
GS-010: An integrative multi-omic approach defines therapeutic pathways associated with altered cell state and chromatin organisation in human liver fibrosis
讲者：Karen Piper Hanley (Manchester, United Kingdom)
专题：General session II
时间：6月23日11:45-12:00 CET
11
IMbrave050：辅助阿替利珠单抗（atezo）+贝伐珠单抗（bev）对比主动监测在肝细胞癌（HCC）切除或消融后疾病复发高风险患者的疗效、安全性和患者报告结果（PRO）
GS-011: IMbrave050: Efficacy, safety and patient-reported outcomes (PROs) for adjuvant atezolizumab (atezo) + bevacizumab (bev) vs active surveillance in hepatocellular carcinoma (HCC) patients at high risk of disease recurrence after resection or ablation
讲者：Ahmed Kaseb (Houston, United States)
专题：General session II
时间：6月23日12:00-12:15 CET
12
III期D-LIVR研究的第48周结果:评估利托那韦与Lonafarnib联合或不联合聚乙二醇干扰素α在慢性丁型肝炎患者中的安全性和有效性
GS-012: Week 48 results of the phase 3 D-LIVR study, a randomized double-blind, placebo-controlled trial evaluating the safety and efficacy of Lonafarnib-boosted with Ritonavir with or without Peginterferon Alfa in patients with chronic hepatitis delta
讲者：Ohad Etzion (Beersheba, Israel)
专题：General session II
时间：6月23日12:15-12:30 CET
最新突破研究
Late Breaker Session
13
辛伐他汀联合利福昔明预防失代偿期肝硬化患者的ACLF——来自一项随机、双盲、安慰剂对照的III期临床试验
LBO-01: Simvastatin plus Rifaximin to prevent ACLF in patients with decompensated cirrhosis. A randomised, double-blind, placebo-controlled, phase-3 trial: the liverhope efficacy trial
讲者：Elisa Pose (Barcrlona, Spain)
专题：Late Breaker
时间：6月24日11:00-11:15 CET
14
VIR-2218联合或不联合聚乙二醇干扰素α治疗慢性乙型肝炎病毒感染患者的安全性和有效性：治疗后随访
LBO-02: Safety and efficacy of VIR-2218 with or without pegylated interferon alfa in virally-suppressed participants with chronic hepatitis B virus infection: post-treatment follow-up
讲者：Man-Fung Yuen (Hong Kong SAR, Hong Kong)
专题：Late Breaker
时间：6月24日11:15-11:30 CET
15
一项评估Cilofexor治疗非肝硬化原发性硬化性胆管炎（PRIMIS）患者疗效和安全性的III期随机、双盲、安慰剂对照研究
LBO-03：A phase 3, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of cilofexor in patients with non-cirrhotic primary sclerosing cholangitis (PRIMIS)
讲者：Michael Trauner (Vienna, Austria)
专题：Late Breaker
时间：6月24日11:30-11:45 CET
16
对肝细胞癌数字图像的深度学习可预测对阿替利珠单抗+贝伐珠单抗的敏感性
LBO-04: Deep learning predicts sensitivity to atezolizumab-bevacizumab from digital slides of hepatocellular carcinoma
讲者：Qinghe Zeng (Paris, France)
专题：Late Breaker
时间：6月24日11:45-12:00 CET
17
Pegozafermin治疗纤维化F2/F3期非酒精性脂肪性肝炎患者——来自一项多中心、随机、双盲、安慰剂对照的IIb期试验（ENLIVEN）
LBO-05: Pegozafermin for the treatment of non-alcoholic steatohepatitis patients with F2/F3 fibrosis: a multi-center, randomized, double-blind, placebo-controlled Phase 2b trial (ENLIVEN)
讲者：Rohit Loomba (La Jolla, United States)
专题：Late Breaker
时间：6月24日12:00-12:15 CET
18
CAMARO试验：麦考酚吗乙酯在缓解初治自身免疫性肝炎方面优于硫唑嘌呤
LBO-06：Mycophenolate mofetil is superior to azathioprine for the induction of remission in treatment-naive autoimmune hepatitis [CAMARO trial]
讲者：Romée Snijders (Nijmegen, Netherlands)
专题：Late Breaker
时间：6月24日12:15-12:30 CET
关注《国际肝病》，解锁重磅研究最新进展，陆续揭晓入选本届大会口头报告和壁报交流的中国专家团队。
往期回顾
2023-06-19
声明：本文仅供医疗卫生专业人士了解最新医药资讯参考使用，不代表本平台观点。该信息不能以任何方式取代专业的医疗指导，也不应被视为诊疗建议，如果该信息被用于资讯以外的目的，本站及作者不承担相关责任。
（来源：《国际肝病》编辑部）